CNBC’s Jim Cramer explained what made shares of Johnson & Johnson rise after the company posted its quarterly report.

The health sector is witnessing notable developments. Bristol Myers and Pfizer are offering Eliquis at a discounted rate.

J&J's diversified business, robust pipeline, and strong free cash flow provide stability, despite legal challenges. Read more ...

Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced the signing of a letter of intent to lease ...

"We launched the Humankind 100 four years ago to help people understand the companies best supporting their quality of life and to encourage companies to continue striving for progress," said James ...

Johnson & Johnson shows steady growth in Q2, driven by medtech and oncology, yet talc litigation overshadows. Click for my ...

Johnson & Johnson halved its expectations for costs this year related to new tariffs and raised its full-year sales and ...

Shares of Johnson & Johnson climbed 4.5% in morning trading, enough to pace the S&P 500 index's SPX gainers. They were also headed for the biggest one-day gain since they rallied 4.6% on May 1, 2024.

Ashwin Kishtagari, MD, of Vanderbilt University Medical Center in Nashville, summarizes 7 studies presented at the EHA 2025 Congress.

Analysts expect Johnson & Johnson to report an earnings per share (EPS) of $2.67. Johnson & Johnson bulls will hope to hear ...